Novavax has reached an agreement to transfer the lease of its global headquarters in Gaithersburg, Maryland, to AstraZeneca in a move reflecting the vaccine maker’s ongoing cost-cutting and restructuring strategy. The deal, valued at approximately $60 million, marks another significant step in Novavax’s effort to consolidate operations and reduce overhead following several challenging quarters.
The lease transfer covers roughly 170,000 square feet of office and laboratory space that Novavax had occupied as its primary corporate base. AstraZeneca, which already has a substantial presence in the Gaithersburg area, plans to use the site to expand its research and development operations focused on immunology and infectious disease.
Novavax stated that the transaction will streamline its real estate footprint and strengthen its financial position as it shifts focus toward advancing its updated COVID-19 vaccine and seasonal influenza programs. The company will continue limited R&D activities at nearby facilities but will centralize key business functions to improve efficiency.
AstraZeneca confirmed that it expects to take control of the Gaithersburg premises by early 2026, integrating the space into its existing regional campus network. The U.K.-based company said the investment underscores its long-term commitment to U.S.-based innovation and talent development.
The transaction follows Novavax’s broader restructuring plan announced earlier this year, aimed at achieving sustainable profitability by 2026 through workforce reductions, program prioritization, and streamlined operations.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!